Background. Cardiovascular disease is the leading cause of mortality among renal transplant recipients. In the general population, coronary artery calcification (CAC) and progression of CAC are predictors of future cardiac risk. We conducted a study to determine the progression of CAC in renal transplant recipients; we also examined the factors associated with progression and the impact of the analytic methods used to determine CAC progression. Methods. We used multi-detector computed tomography to examine CAC in 150 prevalent renal transplant recipients, who did not have a documented cardiovascular disease. A baseline and a follow-up scan were performed and changes in CAC scores were evaluated in each patient individually, to calculate the incidence of CAC progression. Multivariate logistic regression analysis was used to evaluate the determinants of CAC progression. Results. Baseline CAC prevalence was 35.3% and the mean CAC score was 60.0 6 174.8. At follow-up scan that was performed after an average of 2.8 6 0.4 years, CAC prevalence increased to 64.6% and the mean CAC score to 94.9 6 245.7. Progression of individual CAC score was found between 28.0 and 38.0%, depending on the method used to define progression. In patients with baseline CAC, median annualized rate of CAC progression was 11.1. Baseline CAC, high triglyceride and bisphosphonate use were the independent determinants of CAC progression. Conclusions. Renal transplantation does not stop or reverse CAC. Progression of CAC is the usual evolution pattern of CAC in renal transplant recipients. Beside baseline CAC, high triglyceride level and bisphosphonate use were associated with progression of CAC.
Introduction
Cardiovascular disease is the leading cause of mortality among renal transplant recipients [1, 2] . In the general population, measurement of coronary artery calcification (CAC) score is a relatively new method that can be used to detect and measure cardiovascular risk [3] [4] [5] [6] [7] [8] . Recently, it has been suggested that CAC progression may be a more accurate predictor of future cardiac risk than baseline CAC alone [9, 10] .
In patients with end-stage renal disease, the extent of arterial calcification represents the aggregate of both atherosclerotic and medial wall calcification [11] . Previous studies showed that CAC is highly prevalent and severe in renal transplant recipients [12] [13] [14] [15] [16] [17] [18] [19] [20] . In these patients, prognostic implications of high CAC scores are not clear and there is a debate on whether CAC progresses or not following kidney transplantation [12, 14, 16, 18, 19] .
Recently, in a cross-sectional study, we showed that high CAC scores are associated with symptoms of coronary ischaemia and there is a trend towards higher rates of coronary ischaemia by myocardial scintigraphy in renal transplantation patients with severe CAC [20] . Therefore, we suggested that in renal transplant recipients with coronary ischaemia, intimal calcification can be an important contributor of total calcification burden. A different progression pattern can be expected in these patients.
In this prospective study, we aimed to examine timedependent changes in CAC scores in a cohort of renal transplantation patients that do not have documented coronary artery disease. We also examined the factors associated with CAC progression and the impact of analytic methods used to determine CAC progression. [20] . The study protocol was approved by the local medical ethics committee (protocol number: 18578). The study was conducted in accordance with the principles of the Declaration of Helsinki.
Only adult renal transplant recipients (!18 years of age), who gave an inform consent were recruited to the study. Pregnant patients, patients with malignancy or patients in whom time on transplantation is <3 months were excluded from the study. In summary, in the cross-sectional study, data on history of coronary artery disease (myocardial infarction, coronary revascularization procedure or coronary artery disease documented by angiography) were collected from patient files and with interviews, angina pectoris was sought by a physician using the Rose questionnaire and then the CAC score was measured using multi-detector computed tomography (MDCT) and myocardial perfusion scintigraphy (MPS) was performed in patients with a CAC score >100 [20] .
Following the cross-sectional data, collection patients with angina pectoris, abnormal MPS or CAC score >400 were referred to the cardiology department, further cardiovascular workup and treatment were planned by cardiologists who were not part of the study. We wanted to examine the progression of CAC in patients who did not have coronary artery disease; therefore, 12 patients with documented coronary artery disease were not eligible for the second MDCT scan (Figure 1 ). In the follow-up group, there were no patients with a history of cerebrovascular or peripheral vascular disease.
The patients were followed up in the outpatient clinic. The frequencies of regular visits were planned individually according to clinical status of each patient. Generally, the following schedule was used: during the first year of the transplantation; monthly visits, 1-3 years after transplantation; visits every 2 or 3 months, following the third year of the transplantation and visits every 4 or 6 months. At every visit, blood pressure was measured by a nurse or a physician and laboratory parameters were examined. Apart from routine biochemical evaluation, lipid fractions were measured at least every 6 months. Parathyroid hormone (PTH) levels were measured during the recruitment (cross-sectional phase) and at the time of second MDCT scan.
Standard immunosuppressive protocol consisted of induction therapy with rabbit anti-thymocyte globulin (in cadaveric transplantations) or basiliximab (in high-risk living transplantations), followed by maintenance therapy with a calcineurin inhibitor (tacrolimus or cyclosporine), mycophenolate mofetil, mycophenolate sodium or azathioprine and low-dose prednisolone (5 mg/day). In some patients, m-TOR inhibitors were introduced during follow-up. During the routine follow-up, calcium supplement and/or active vitamin D were prescribed according to the physician's preferences for prevention and management of post-transplant osteoporosis. Bisphosphonate therapy (alendronate 70 mg/week) was prescribed only in patients who have low (lumber or femoral T score <À2.5) bone mineral density (BMD).
Between March 2009 and June 2010, a second MDCT scan was performed in 150 patients (Figure 1 ).
Data collection
Definitions and methods used during clinical and laboratory assessment were previously described in detail [20] . Data on drugs, blood pressure and biochemical parameters were collected from patient files. Average values for the entire follow-up period were calculated and these mean values were used to represent follow-up data. Taking of the drug for more than half of the whole follow-up period was accepted as drug use.
Imaging procedures
The second MDCT scan was performed with the same equipment (SO-MATOM Sensation 16 Cardiac; Siemens AG, Erlangen, Germany) and procedures that were used during the cross-sectional phase (first MDCT scan) [20] . CAC scores were calculated according to the Agatston method. The presence of CAC was defined by a CAC score of !1. All follow-up, MDCT scans were scored by the same radiologist (D.C.) who also evaluated the first scans. Eighteen randomly selected scans that were examined during the first cross-sectional study [median CAC score:0; range (0-613.4)] and that were digitally recorded were reexamined during the evaluation of the second scans. All scans were reclassified correctly according to presence of CAC (j ¼ 1), and correlation coefficient between examinations was very high (r ¼ 0.99). According to Bland-Altman analysis, mean difference between repeated measurements was 4.47 and the limits of the agreement were À34.5 and 42.7 (the plot is shown in Supplementary Figure 1) .
Evaluation of CAC progression
We used three different approaches to evaluate time-dependent changes in CAC score, these methods were previously used to evaluate CAC progression in renal transplant recipients [16, 18, 19] . Firstly, for patients with detectable CAC at baseline, progress was defined as a CAC score change !25% and subjects with a CAC score of 0 and follow-up score !4 were considered to have progressed [14] . Secondly, progression of calcification was defined as a difference between the follow-up square-root transformed score (SRC) and the baseline SRC !2.5 [21] . Thirdly, in subjects with detectable CAC at baseline, the smallest statistically significant interval change was defined as AE À 4:933 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi baseline CAC score p Á and in subjects with a CAC score of 0 a follow-up CAC score >11.6 qualifies progression [22] .
The difference between the second and the first scan was divided by the time in years between scans to compute an annualized rate of change [(second CAC score À baseline CAC score)/interval between scans] [14] .
Statistical analysis
Data are expressed as mean AE SD, if not stated otherwise. Categorical variables were compared using chi-square tests and two-sided exact significances (Fisher's exact test) were reported. Continuous variables were compared using Student's t-test. Multivariate logistic regression analysis was used to evaluate the determinants of CAC progression.
All tests were performed using SPSS for Windows, version 15.0, software (SPSS Inc, Chicago, IL). Figures were prepared using MicrosoftÒ Office Ó 2007 software (Microsoft corp., Redmond, WA). P <0.05 is considered statistically significant.
Results

Demographic characteristics, clinical and laboratory data
The demographic characteristics, clinical and laboratory data for the 150 renal transplant recipients are listed in Table 1 . Study participants were Caucasian, predominantly male and mostly young or middle aged and they had a living donor transplant (Table 1) . Preemptive transplantation was performed in two (1.3%) patients.
According to body mass index (BMI), 39.3% of the patients were overweight (BMI >25) and 14.7% were obese (BMI >30). The majority of the patients had hypertension, however; systolic and diastolic blood pressure levels were generally within normal limits ( Table 1 ). The prevalence of diabetes was low (Table 1) . No new case of diabetes or hypertension was observed during the follow-up. Dyslipidaemia was highly prevalent and 75.3% of the patients had at least one type of lipid abnormality or were taking lipid-lowering medications.
Baseline glomerular filtration rate was >30 mL/min/ 1.73m 2 in all but one patient. Calcium and phosphorus levels were generally within the normal range of the laboratory; however, PTH levels were high (upper limit for laboratory 72 pg/mL) in 71.3% of the patients. 
Coronary artery calcification
According to the baseline scan, CAC was present in 53 patients (35.3%) and mean CAC score was 60.0 AE 174.8. After a mean follow-up period of 33.8 AE 4.6 (median: 34, range 25-50) months, a second scan was performed. CAC was more frequent (n ¼ 97, 64.6%, P ¼ 0.000) and more severe (94.9 AE 245.7, P ¼ 0.000) in the second scan, compared to that of the baseline scan ( Table 2) . Distribution of CAC scores among patients is shown in Figure 2 . At the end of the follow-up that was on average 2.8 years, 34 of the 97 (35.0%) patients with no baseline CAC converted to a positive score, for an estimated incidence rate or 12.5% per year. Progression of individual CAC scores was evaluated by different methods (Table 2 ). According to the method proposed by Schankel et al., CAC progressed in 57 patients (38%). Progression was observed in 43 (28.7%) and 42 (28.0%) patients according to the methods used by Hoakson et al. and Sevrukov et al., respectively. Regression of CAC was observed only in two (1.3%) patients in both methods. As the results with both methods were similar (j ¼ 0.89; P ¼ 0.000) and the method of Sevrukov et al. included definitions for Agatston scoring, we used it to define the progression for the following analysis. Incidence of progression increased parallel to baseline CAC score (Supplementary Figure 2) . Annual CAC progression among different patient subgroups is shown in Table 2 . In patients with baseline CAC, median annual CAC progression was 11.1 (À51.5 to 185.5).
Determinants of CAC progression
Clinical and biochemical characteristics of renal transplant recipients, according to the presence or absence of CAC progression are shown in Table 3 . It should be noted that the duration between two scans were similar between the two groups ( Table 3) . Comparisons of progressors with non-progressors according to drug use are shown in Table  4 . Based on univariate analysis, higher donor age, longer time on transplantation, presence of baseline CAC, high baseline CAC score and high triglyceride levels were significantly associated with CAC progression (Table 3) .
We constructed two multivariate logistic regression models; in both models, variables were selected based on the comparison of progressors with non-progressors. In the first model, variables that were associated with CAC at a significance level of P <0.05 were used. In the second one, variables that were associated with CAC at a significance level of P <0.1 were used. In both models, baseline CAC and triglycerides level were determinants of CAC progression, moreover, according to the second model, bisphosphonate use was another determinant of CAC (Table 5) . Bisphosphonates were generally continued (excluding three patients) during the whole follow-up period. [22] . ACP, annual coronary artery calcification progression.
Discussion
We examined a fairly large number of renal transplant recipients and found that CAC progresses after transplantation. To the best of knowledge, this is the largest study with the longest follow-up that examines CAC progression in renal transplant recipients. The results of the studies on progression of CAC are not uniform [12, 14, [16] [17] [18] [19] . Early studies performed with a limited number of patients suggested that progression of CAC slows down or stops following an early phase of progression [12, 14] . More recently, larger studies were performed to evaluate CAC progression in renal transplant recipients. Schankel et al. [16] examined 82 asymptomatic patients and concluded that CAC progression is seen in a quarter of their cohort that was followed-up for 1.77 AE 0.57 years. Mazzaferro et al. [18] examined 41 renal transplant recipients and a control group composed of 30 dialysis patients; the patients were followed up for nearly 2 years and progression was observed in 12.2% of the renal transplant recipients. They concluded that renal transplantation favourably affects but does not halt CAC progression and improvement of CAC is a very rare event [18] . Finally, Bargnoux et al. [19] examined CAC progression in 76 patients that were followed up for 1 year; CAC progressed in 26.3% of their patients and interestingly regressed in 14.5%.
Obviously, these discrepancies are partially related to demographic and clinical differences of the study populations. Additionally, there are some methodological caveats that should be taken into account in CAC progression studies. Firstly, there is a clearly established interscan variability of CAC scoring [21, 22] . Without accounting for the relation between interscan variability and the CAC score, a bias may be introduced in the evaluation of changes in CAC [21] . Recently, it has been recommended to use the transformed square root method of Hoakson for quantifying progression [23] . We used three different methods to define progression of CAC in renal transplant [23] . For the purpose of interventional trials, longer intervals than 1 year and likely at least 3 years were proposed [24, 25] . Recently, Min et al. [26] examined 422 non-kidney disease patients with a baseline CAC score of 0 and proposed that a CAC scoring should not be performed for 4 years in individuals with a baseline CAC score of 0. In our study, the median follow-up time was 2.83 years and this is the longest duration in CAC progression studies performed in renal transplant recipients. Thirdly, in patients with chronic kidney disease, CAC score reflects the aggregate of medial and intimal wall calcification. Intimal wall calcification is associated with atherosclerosis, whereas medial wall calcification is mainly associated with abnormal bone mineral metabolism [11] . A different progression pattern can be expected for each type of calcification. Therefore, in the cross-sectional phase of our study, we intended to identify the patients with coronary heart disease and we excluded them from the follow-up study. We examined relatively younger patients compared to previous studies, however, the rate of progression was higher in our study group [16, 18, 19] . We used the same criteria used by each previous study to define progression; therefore, we think that our high progression rate can be explained by our longer follow-up duration. Indeed, according to the Multi-Ethnic Study of Atherosclerosis (MESA), each additional year of follow-up was associated with an extra 17.5 Agatston unit of progression on average [27] . Moreover, Min et al. [26] have recently shown that in patients with a baseline CAC score of 0, progression of CAC was nonlinear and extremely low in the first 2 years. On the other hand, we found that in patients with CAC at baseline, median annual CAC progression was 11.1, and these data were in agreement with previous work by Bargnoux et al. and Shankel et al. that reported median annual CAC progression as 14 and 17.5, respectively [16, 19] . An interesting finding is that in our study, only two patients had regression of CAC score. In a 1-year follow-up study, Bargnoux et al. [19] reported regression of CAC in 14.5% of their patients. Our data are in line with the findings of previous works with longer follow-up durations [16, 18] . We suggest that renal transplantation can improve CAC in some patients in the short term but in the long term, progression is the usual process.
Our study lacks a control group. However, two largescale studies can provide valuable information to compare our progression rates with non-kidney disease patients [26, 27] . In our study in patients without baseline CAC, the yearly incidence rate of CAC was 12.5% and the cumulative CAC incidence at the end of the follow-up was 35.0%. According to the MESA study, in patients without CAC at baseline, estimated incidence rate for CAC was 6.6%/year in the whole group and 10.3%/year in Caucasians [27] . It should be noted that the MESA cohort was much older than our patients (average age: 62.0 versus 38.7 years). Moreover, recently, Min et al. [26] suggested that the assumption of a constant rate of CAC progression might be incorrect and that there is a lag period in which an individual without CAC shows no progression. They found the cumulative CAC incidence to be 7.4% at the third year in patients without baseline CAC. These data suggest that the incidence of CAC progression is higher in our renal transplant recipients.
We found an independent association between CAC progression and baseline CAC score, triglyceride level and bisphosphonate use. The presence of CAC itself was a strong predictor of further CAC progression over time, as shown in previous studies both in renal transplant recipients and non-kidney disease patients [16, 18, 19, 26] . Both a high CAC score and progression of CAC were associated with a high cardiovascular mortality in the general population [3] [4] [5] [6] [7] [8] [9] [10] . According to recent studies, aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation [28, 29] . However, it is still not clear whether a high CAC score predicts cardiovascular or general mortality in renal transplant recipients especially in patients without documented cardiovascular disease.
Similar to our results, triglyceride level was associated with CAC progression in previous work including the MESA Progression of coronary calcification 2105 study [27] . However, we did not find an association with other lipid parameters such as low-density lipoprotein (LDL) cholesterol. High LDL cholesterol is mainly associated with atherosclerotic lesions; hence intimal calcification. We excluded patients with documented coronary heart disease, moreover, in renal transplant recipients, there is a complex association between high LDL cholesterol, CAC and statin use. Indeed, we and others have shown a negative association between LDL cholesterol and CAC in these patients [19, 20] . Bisphosphonate use was another determinant of CAC progression. Bisphosphonates are potent inhibitors of bone turnover [30, 31] , and at least in CKD patients, low bone turnover (adynamic bone disease) is associated with vascular calcification [31] . It should be noted that albeit statistically non-significant calcium and vitamin D use was also more common in patients in whom CAC progressed. Previous work revealed a complex association between bisphosphonate use and cardiovascular calcification. According to a recent study, bisphosphonate use was associated with a high prevalence of cardiovascular calcification in woman aged <65 [32] . According to animal studies, these drugs generally inhibit vascular calcification in different animal models [33] . There have been varying responses in clinical studies; studies performed in the general population have reported no difference in vascular calcification with bisphosphonate administration, however, according to a paucity of clinical data in patients with CKD, these drugs can improve vascular calcifications [33] . On the other hand, according to some studies, there is an inverse relation between bone mineral density (BMD) and vascular calcifications [34, 35] . Bisphosphonates were used exclusively in patients with low BMD. Therefore, bisphosphonate use can be a confounder and the association between bisphosphonate use and CAC progression can be a reflection of an inverse relation between BMD and CAC. Obviously, our study was not designed to reveal these complex associations.
Our study has also some weaknesses. Most important is the lack of an age-and sex-matched control group that can be used to compare the rate of progression. We did not collect data on BMD and proteinuria, additionally, data on drugs were dichotomous rather than quantitative. We might have overlooked same patients with subclinical atherosclerosis, and in this case, possibly intimal calcification also contributed to total CAC score of our patients. In our clinic, kidney transplantation is mainly performed from living donors and usually, our diabetic patients with multiple comorbidities were not good candidates for living donor transplantation. Therefore, the relatively low number of diabetics reflects centre policy rather than selection bias. Finally, we examined a special group excluding patients with documented cardiovascular disease; therefore, generalizability of our results can be limited.
In conclusion, in this study, we examined the progression of CAC in renal transplant recipients by excluding the patients with documented coronary artery disease. We found that progression of CAC is the usual evolution pattern of CAC in renal transplant recipients. Beside a high baseline CAC score, high triglyceride level and bisphosphonates use were associated with CAC progression. Further studies are needed to better analyse these associations and to develop preventive strategies for the progression of CAC.
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